BioSpace News Archive

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced today that it will be participating in Citi’s 14th Annual Biotech Conference in Boston.

Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatment, compared to oral immediate-release carbidopa/levodopa in people with Parkinson’s disease experiencing motor fluctuations.

In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available on the Company’s website starting at 8:30 a.m. Eastern Time/ 7:30 a.m. Central Time on Wednesday, September 4, 2019.

The global testicular cancer drugs market size is poised to grow by USD 421 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of over 4% during the forecast period.

Top researcher Ajay Goel, PhD. and his team discovered several ways that this natural botanical could aid in the fight against cancer.

PTCE will offer six continuing education sessions at the seventh Annual National Association of Specialty Pharmacy Annual Meeting & Expo

Seasoned Digital Health Executive Will Further Propel Company’s Market Expansion

The Massachusetts Biotechnology Council(MassBio®) today released its 2019 Industry Snapshot report, which shows that the Massachusetts biopharma industry experienced the highest year-over-year employment growth in over a decade, adding over 4,300 new jobs from 2017 to 2018 for 6.4% growth.

Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that its lead product candidate, ACX-362E, has successfully completed the 68-subject, double-blind, placebo-controlled, multiple-ascending dose Phase 1 clinical trial of ACX-362E in healthy volunteers

In one of the most substantial studies of a skin health supplement, BioCell Collagen®, was found to visibly reduce common signs of skin aging, including lines and wrinkles, within 12 weeks of daily use.